
Understanding Your Breast Cancer Pathology Report: Type, Grade, ER, PR, HER2 and Ki-67
The pathology report is the most important information for planning breast cancer treatment. It tells you what type of cancer it is, how aggressive it is, and which treatments it is likely to respond to, through ER, PR, HER2 and Ki-67. These divide breast cancer into three main groups: HR+/HER2−, HER2-positive and triple-negative. This article explains each section so you can read your own report, and at Namarak Hospital our breast surgeons go through your results line by line before planning treatment.
1. Cancer type (histologic type)
Ductal carcinoma in situ (DCIS), stage 0 — not yet invasive beyond the ducts; see What is DCIS?
Invasive carcinoma of no special type (NST), formerly invasive ductal carcinoma — the most common, about 70–80%
Invasive lobular carcinoma (ILC) — about 10–15%; tends to spread in sheets and can be hard to see on imaging
Special types such as mucinous or tubular (often a good prognosis) or metaplastic (often triple-negative)
2. Grade (histologic grade)
Grade describes how abnormal the cells look and how fast they divide, using the Nottingham system: grade 1 (slow-growing), grade 2 (intermediate) and grade 3 (fast-growing). A high grade does not mean the cancer cannot be treated, but it influences decisions about chemotherapy.
3. Hormone receptors: ER and PR
ER (estrogen receptor) and PR (progesterone receptor) are reported as the percentage of cells that stain positive
ER 1% or higher is hormone receptor–positive and benefits from endocrine therapy, especially when the level is high — see HR+/HER2− breast cancer
ER 1–10% (ER-low positive) — responds less to endocrine therapy and often behaves like triple-negative disease; decisions are individualized
ER below 1% is hormone receptor–negative
4. HER2
HER2 is a growth-promoting protein. It is tested by immunohistochemistry (IHC, scored 0 to 3+), and a 2+ result is confirmed by in situ hybridization (ISH: FISH or SISH).
IHC 3+ or ISH-positive = HER2-positive, which benefits from HER2-targeted therapy — see HER2-positive breast cancer
IHC 1+ or 2+ (ISH-negative) = HER2-low
IHC 0 with faint staining = HER2-ultralow
HER2-low and ultralow matter in metastatic disease because the ADC trastuzumab deruxtecan (T-DXd) may be an option — see HER2-low and HER2-ultralow
Specimen handling affects accuracy. The time from removal of tissue to fixation (cold ischemia time) should not exceed 1 hour. Namarak keeps cold ischemia time within 1 hour in line with international standards, with an average of no more than 30 minutes.
5. Ki-67
Ki-67 shows the proportion of dividing cells. A low value (about 5% or less) suggests slow growth and a high value (30% or more) fast growth; values in between are harder to interpret. Ki-67 is used with other factors in HR+ disease and to select some early-stage patients for CDK4/6 inhibitors.
6. Breast cancer subtypes
HR+/HER2− — the most common; treated mainly with endocrine therapy, with chemotherapy depending on risk
HER2-positive — treated with HER2-targeted drugs plus chemotherapy
Triple-negative (TNBC) — ER, PR and HER2 all negative; treated with chemotherapy plus immunotherapy — see What is TNBC?
7. Information from the surgical specimen
Tumor size and lymphovascular invasion (LVI)
Surgical margins — invasive cancer: no tumor at the inked edge (“no ink on tumor”) is adequate; DCIS: a margin of at least 2 mm is recommended
Lymph nodes — number examined and number involved, classified as macrometastasis, micrometastasis or isolated tumor cells
Stage (pTNM) according to AJCC 8th edition, which also incorporates grade, ER, PR and HER2 — see Breast cancer staging
8. Results after treatment before surgery
pCR (pathologic complete response) — no invasive cancer left in the breast or lymph nodes, a very good sign
Residual disease — cancer remains; it is graded by the Residual Cancer Burden (RCB) score, and additional treatment after surgery, such as capecitabine, olaparib or T-DM1 depending on type, is usually given
Frequently asked questions (FAQ)
What does ER-positive, PR-positive, HER2-negative mean?
It means hormone receptor–positive, HER2-negative breast cancer, the most common type. It is treated mainly with endocrine therapy, with chemotherapy considered according to stage, grade or a tumor genomic test.
Does HER2 2+ mean HER2-positive?
Not yet. It must be confirmed by ISH: if positive it is HER2-positive, and if negative it is classified as HER2-low.
Is a high Ki-67 dangerous?
A high Ki-67 means the cancer divides quickly, but such cancers often respond well to chemotherapy. It is one of several factors doctors use to choose treatment.
What counts as an adequate surgical margin?
For invasive cancer, no tumor at the inked edge is adequate. For DCIS, a margin of at least 2 mm is recommended.
Can biopsy and surgical results differ?
Yes. A needle biopsy samples only a small part of the tumor; the surgical specimen gives complete information on size, lymph nodes and margins, and receptors are sometimes re-tested.
About Namarak Hospital
Namarak Hospital is a specialized breast and breast cancer hospital in Bangkok, providing complete care in one place — from diagnosis with 3D mammography, ultrasound, automated breast ultrasound (ABUS) and biopsy to comprehensive breast cancer treatment, including breast-conserving and reconstructive surgery, intraoperative radiotherapy (IORT), chemotherapy, targeted therapy and endocrine therapy, planned by a multidisciplinary team according to the latest international guidelines. See Breast cancer treatment: a complete guide, contact us on LINE, tel. +66 2 059 0245, or our Second Opinion service.
Related articles
References
Allison KH, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol 2020;38:1346–66
Wolff AC, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–CAP Guideline Update. J Clin Oncol 2023;41:3867–72
Nielsen TO, et al. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 2021;113:808–19
WHO Classification of Tumours: Breast Tumours, 5th Edition
NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 4.2026
Medically reviewed by: Namarak Hospital medical team · Last checked: 17 November 2026 · This information is for general education and is not individual medical advice. Please consult your doctor for diagnosis and treatment suited to you.





Comments